Cleerly ISCHEMIA vs prolaio eVO2peak Module

Cleerly ISCHEMIA offers a web-based platform with comprehensive, interactive reports for physicians to review results in depth. In contrast, the prolaio eVO2peak Module explicitly states it lacks a direct user interface, relying on integration for output interpretation by clinical users. This makes Cleerly ISCHEMIA more directly usable for physician interaction.

Cleerly ISCHEMIA provides a comprehensive 3-in-1 assessment of atherosclerosis, stenosis, and ischemia from a single CCTA, including non-invasive FFR estimation and detailed plaque characterization. It has demonstrated high diagnostic accuracy and prognostic utility for major adverse cardiovascular events (MACE) in multiple clinical trials, outperforming or performing equivalently to other noninvasive measures. While prolaio eVO2peak Module offers valuable adjunctive information by estimating peak oxygen consumption from wearable data, Cleerly's direct diagnostic and prognostic capabilities for coronary artery disease, backed by robust comparative evidence, offer a more profound clinical impact.

Both tools require direct contact for pricing details, making a direct cost comparison impossible. However, Cleerly ISCHEMIA has secured a Category I CPTu00ae code (75580) for its service, which is a significant advantage for reimbursement and demonstrates recognized value within the healthcare billing system. This established reimbursement pathway enhances its value proposition for providers.

Both tools are FDA-cleared, HIPAA compliant, and offer Business Associate Agreements (BAAs), establishing a strong foundation for enterprise use. Cleerly ISCHEMIA explicitly details its integration capabilities with existing radiology workflows via API (e.g., PowerScribe) and a dedicated Cleerly Proxy for data transfer, indicating a more mature approach to enterprise integration. Prolaio eVO2peak Module is cloud-based and processes remote sensor data, but its broader system integration is less explicitly defined.

Cleerly ISCHEMIA's ability to provide a comprehensive, non-invasive 3-in-1 assessment of atherosclerosis, stenosis, and ischemia, including non-invasive FFR estimation and detailed plaque characterization from CCTA, represents a significant advancement in cardiac imaging and diagnosis. While prolaio eVO2peak Module's use of real-world wearable data and deep learning for longitudinal VO2peak estimation is innovative, Cleerly's integrated diagnostic approach from a single CCTA offers a more transformative shift in the current paradigm of heart disease evaluation.

Cleerly explicitly provides dedicated client support channels, including a 'Client Support' contact form and a clear statement about timely assistance. Furthermore, it offers publicly available billing guidelines and coverage policies. While Prolaio mentions documentation for integration, it does not provide the same level of detail regarding customer support channels or public resources.